louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05137496: Ruxolitinib and Methylprednisolone as a First-line Treatment for Macrophage Activation Syndrome
Official title: A Single-center, Prospective, Non-comparative Clinical Trial of Ruxolitinib and Methylprednisolone as a First-line Treatment for Macrophage Activation Syndrome
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Macrophage Activation Syndrome
Lead sponsor: Beijing Friendship Hospital
Sponsor class: OTHER
First posted: 2021-11-30
Enrollment: 40
Sex: ALL
Minimum age (years): 1
Maximum age (years): 75
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The present study was a single-center, prospective, non-comparative in which macrophage activation syndrome patients were selected as the main subjects to evaluate the effect and safety of Ruxolitinib and methylprednisolone regimens as the first-line therapy .


Eligibility criteria: Inclusion Criteria:

1. Meet hemophagocytic lymphohistiocytosis (HLH)-04 diagnostic criteria; patients were diagnosed with autoimmune disease associated HLH (Macrophage activation syndrome, MAS).
2. No HLH induction therapy was performed.
3. The expected survival time is more than 1 month.
4. Serum creatinine ≤ 1.5 times normal；Serum human immunodeficiency virus(HIV) antigen or antibody negative； Hepatitis C virus (HCV) antibody is negative, or HCV antibody is positive, but HCV RNA is negative；HBV copies less than 1E+03 copies/ml.
5. Total bilirubin ≤10 times the upper limit of normal; serum creatinine ≤1.5 times the normal value
6. The left ventricular ejection fraction (LVEF) was normal.
7. No uncontrollable infection.
8. Contraception for both male or female.
9. Informed consent obtained.

Exclusion Criteria:

1. Pregnancy or lactating Women；
2. Allergic to ruxolitinib；
3. Active bleeding of the internal organs；
4. uncontrollable infection；
5. Serious mental illness;
6. Non-melanoma skin cancer history;
7. Patients unable to comply during the trial and/or follow-up phase;
8. Participate in other clinical research at the same time.

Primary outcomes:
measure: Response rate
timeFrame: Change from before and 2,4,6 and 8 weeks after initiating Ruxolitinib combined with methylprednisolone therapy
measure: Progression Free Survival
timeFrame: 2 years
measure: Adverse events
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01631396: Comparison of Two Neuromuscular Anesthetics Reversal in Obese Patient Undergoing Bariatric Surgery
Official title: Comparison of Two Neuromuscular Anesthetics Reversal in Obese Patient Undergoing Bariatric Surgery
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Anesthesia
Surgery
Keywords: Morbid obesity
Bariatric Surgery
Neuromuscular block reversal
Lead sponsor: Assuta Hospital Systems
Sponsor class: OTHER
First posted: 2012-06-29
Enrollment: 40
Sex: ALL
Minimum age (years): 20
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Subjects for the study will be recruited from patients within the community who have sought treatment for morbid obesity by bariatric surgery, are qualified for the surgery and meet all of the eligibility criteria listed below.

Brief summary: The study is a prospective, single center, double arm study aiming at the comparison of 2 commercial neuromuscular block reversal drugs: Neostigmine (Cooper S.A.) and Sugammadex (MSD). A faster recovery from neuromuscular block is expected for patients receiving Sugammadex and this protocol is of high importance for anesthesia of morbid obese patients during bariatric surgery.


Eligibility criteria: Inclusion Criteria:

1. Morbidly obese male or female patients in the age 20-65 that are candidates for bariatric surgery.
2. Patients that can read and understand the fundamental nature of the clinical protocol.
3. Patients must sign the Informed Consent Form.

Exclusion Criteria:

1. Patients treated with drugs that might interact with Rocuronium.
2. Patients with history of malignant hyperthermia.
3. Patients with significant renal disease.
4. Patients with a known allergy to one of the drugs used during anesthesia.
5. Patients with known muscular disease.
6. Patients with severe cardiovascular disease (NYHA\>2)
7. Breast feeding patients
8. Patients refusing to follow the clinical protocol.
9. Patients participating in a different clinical trial.
10. Patients refusing to sign the Informed Consent Form
11. Physician's objection.

Primary outcomes:
measure: Safety of Sugammadex reversal - number of drug-related adverse events with Sugammadex <= that of Neostigmine.
timeFrame: Monitoring nueromuscular reaction from end of anesthesia recovery (in the OR) intil patient is released from hospital (48-72 h post surgery)
Secondary outcomes:
measure: Use of Sugammadex for neuromuscular anaesthesia reversal higher patient satisfaction compared to Neostigmine.
timeFrame: Monitoring nueromuscular reaction from end of anesthesia recovery (in the OR) intil patient is released from hospital (48-72 h post surgery)
Other outcomes:
Locations:
city: Tel Aviv
country: Israel
facility: Assuta Medical Center
Study officials:
affiliation: Medical Director, ICBS-Israeli Center for Bariatric Surgery
name: Asnat Raziel, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00092196: Study of MK0869 for the Prevention of Chemotherapy-Induced Nausea and Vomiting (0869-071)(COMPLETED)
Official title: Open-label Extension to: A Randomized, Double-Blind, Parallel-Group Study Conducted Under In-House Blinding Conditions to Determine the Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Moderately Emetogenic Chemotherapy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Nausea
Vomiting
Breast Neoplasms
Keywords: Chemotherapy-Induced Nausea and Vomiting
Lead sponsor: Merck Sharp & Dohme LLC
Sponsor class: INDUSTRY
First posted: 2004-09-24
Enrollment: 820
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to determine the efficacy and tolerability of an investigational drug for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy.


Eligibility criteria: Inclusion Criteria:

* Patient with a diagnosis of breast cancer requiring treatment with non-cisplatin moderately emetogenic chemotherapy.
* Patient must have completed participation in the main study for this protocol.

Exclusion Criteria:

* Patient has a central nervous system malignancy.
* Patient will receive radiation to the abdomen or pelvis.

Primary outcomes:
measure: Safety and tolerability
Secondary outcomes:
measure: Assessment of adverse experiences using the National Cancer Institute (NCI) criteria
Other outcomes:
Locations:
Study officials:
affiliation: Merck Sharp & Dohme LLC
name: Medical Monitor
role: STUDY_DIRECTOR
References:
citation: Herrstedt J, Muss HB, Warr DG, Hesketh PJ, Eisenberg PD, Raftopoulos H, Grunberg SM, Gabriel M, Rodgers A, Hustad CM, Horgan KJ, Skobieranda F; Aprepitant Moderately Emetogenic Chemotherapy Study Group. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy. Cancer. 2005 Oct 1;104(7):1548-55. doi: 10.1002/cncr.21343.
citation: Warr DG, Hesketh PJ, Gralla RJ, Muss HB, Herrstedt J, Eisenberg PD, Raftopoulos H, Grunberg SM, Gabriel M, Rodgers A, Bohidar N, Klinger G, Hustad CM, Horgan KJ, Skobieranda F. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol. 2005 Apr 20;23(12):2822-30. doi: 10.1200/JCO.2005.09.050.
citation: Aapro MS, Schmoll HJ, Jahn F, Carides AD, Webb RT. Review of the efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in a range of tumor types. Cancer Treat Rev. 2013 Feb;39(1):113-7. doi: 10.1016/j.ctrv.2012.09.002. Epub 2012 Oct 11.
Clinical trial NCT03992196: A Follow-up Study of Rotigotine Patch in Adolescent Subjects With Restless Legs Syndrome
Official title: A Remote, Open-Label, Long-Term, Follow-up Study to Determine the Safety, Tolerability, and Efficacy of Rotigotine Transdermal System as Monotherapy in Adolescents With Restless Legs Syndrome
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE3
Conditions: Restless Legs Syndrome
Keywords: RLS
Neupro
Rotigotine
Lead sponsor: UCB Pharma
Sponsor class: INDUSTRY
First posted: 2019-06-20
Enrollment: 10
Sex: ALL
Minimum age (years): 13
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to assess the long-term safety, tolerability and the long-term efficacy of rotigotine treatment in adolescents with idiopathic Restless Legs Syndrome (RLS).


Eligibility criteria: Inclusion Criteria:

* Subject weighs \>=40 kg
* Subject has completed at least one dose step in SP1006, a previous study of rotigotine in adolescents with Restless Legs Syndrome (RLS), without meeting withdrawal criteria
* Female subjects must be surgically incapable of childbearing, or effectively practicing an acceptable method of contraception (oral/parenteral/implantable hormonal contraceptives, intrauterine device, or barrier and spermicide). Abstinence is an acceptable method. Subjects must agree to use adequate contraception during the study and for 4 weeks after their final dose of study drug
* Subject is expected to benefit from participation, in the opinion of the investigator

Exclusion Criteria:

* Subject is experiencing an ongoing serious Adverse Event (SAE) that is assessed to be related to rotigotine by the investigator or Sponsor
* Subject has active suicidal ideation as indicated by a positive response ("Yes") to either Question 4 or Question 5 of the "Since Last Visit" version of the electronic Columbia Suicide Severity Rating Scale (eC-SSRS) at the final evaluation visit of the previous rotigotine study (ie, Visit 10 of SP1006)

Primary outcomes:
measure: Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)
timeFrame: From Baseline until the Safety Follow-Up Visit (up to 14 Months)
measure: Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Withdrawal of Study Medication
timeFrame: From Baseline until the Safety Follow-Up Visit (up to 14 Months)
Secondary outcomes:
measure: Changes From Baseline in International Restless Legs Rating Scale (IRLS) Sum Score at Visit 9
timeFrame: Visit 9 (Month 12), compared to Baseline (in SP1006)
measure: Changes From Baseline in Clinical Global Impressions (CGI) Item 1 at Visit 9
timeFrame: Visit 9 (Month 12), compared to Baseline (in SP1006)
measure: Changes From Baseline in Restless Legs-6 Rating Scales (RLS-6) at Visit 9
timeFrame: Visit 9 (Month 12), compared to Baseline (in SP1006)
Other outcomes:
Locations:
city: Culver City
country: United States
facility: Rl0007 101
state: California
Study officials:
affiliation: 001 844 599 2273
name: UCB Cares
role: STUDY_DIRECTOR
References:
Clinical trial NCT06508996: Xpert Hepatitis-C Virus (HCV) Test on the GeneXpert Xpress System
Official title: Clinical Evaluation of the Xpert® HCV Test on the GeneXpert® Xpress System
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: HCV
Lead sponsor: Cepheid
Sponsor class: INDUSTRY
Collaborators: name: Emory University
First posted: 2024-07-19
Enrollment: 1012
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Specimens collected from individuals showing signs and symptoms and/or at risk of HCV infection

Brief summary: A multi-site prospective, all comers study that was conducted at geographically diverse locations in the United States.

Detailed description: Whole blood specimens were collected from consented individuals with signs and symptoms and/or individuals at-risk of HCV infection, irrespective of HCV antibody status at a single timepoint.

Eligibility criteria: Inclusion Criteria:

* Participant was ≥18 years old
* Participant was not on treatment at time of enrollment based on review of medical records or self-reported
* Participant had signs and symptoms and/or is considered at-risk of HCV infection

Exclusion Criteria:

* Clinician assessed that the participant was not suitable for inclusion

Primary outcomes:
measure: Percent Agreement compared to Patient infected status (PIS)
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: Lexington
country: United States
facility: University of Kentucky
state: Kentucky
Study officials:
affiliation: University of Kentucky College of Medicine
name: Jennifer Havens
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05744596: Assessment of the Role of Incisura Biopsy in the Staging of Chronic Gastritis
Official title: Assessment of the Role of INCisura Biopsy in incrEASing the Stage of Chronic Gastritis
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Chronic; Gastritis, Atrophic
Lead sponsor: Clinical Hospital Colentina
Sponsor class: OTHER
First posted: 2023-02-27
Enrollment: 400
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: All patients over 18 years undergoing upper GI endoscopy are considered eligible for this study, regardless of gender, age or indication.

Brief summary: This prospective multicenter study investigates the added benefit of incisura biopsy to correct identification of patients with high-risk chronic gastritis (OLGA stages III-IV). It compares a biopsy protocol with and without a single incisura biopsy in a non-inferiority design.


Eligibility criteria: Inclusion Criteria:

* indication to perform upper GI endoscopy for diagnosis or surveillance

Exclusion Criteria:

* lack of informed consent, previously diagnosed advanced gastric cancer, incomplete endoscopy, surgically altered stomach

Primary outcomes:
measure: prevalence of OLGA III-IV
timeFrame: at time of enrollment
Secondary outcomes:
measure: prevalence of OLGIM III-IV
timeFrame: at time of enrollment
Other outcomes:
Locations:
city: Bucharest
country: Romania
facility: Colentina Clinical Hospital
Study officials:
References:
Clinical trial NCT04833296: Ropivacaine Use in Interscalene Block; What is the Minimal Effective Analgesic Concentration (MEAC 90)
Official title: Ropivacaine Use in Interscalene Block; What is the Minimal Effective Analgesic Concentration (MEAC 90)
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Postoperative Pain
Lead sponsor: Healthpoint Hospital
Sponsor class: OTHER
First posted: 2021-04-06
Enrollment: 45
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study aim to calculate the minimal effective ropivacaine concentration required achieve successful analgesic interscalene block in 90% of patients (MEAC90)

Detailed description: * Before induction of general anesthesia, all patients will receive interscalene block using 15ml of ropivacaine which concentration will be based on the response of the previous patient.
* Based on biased-coin design up-down sequential method: if patient has pain free recovery, a successful block, the next patient will be randomized to receive either the same ropivacaine concentration or a concentration 0.01% w/v less. However, if he has an unsuccessful block, the next patient will receive a concentration 0.01% w/v higher.
* Patients with pain free recovery will be considered to have positive response.
* Patients' responses will be analyzed to calculate the MEAC90.

Eligibility criteria: Inclusion Criteria:

* Patients, who are scheduled for shoulder arthroscopy

Exclusion Criteria:

* - \<18 y,
* ASA physical class greater \>III

  * BMI \>40 has any contraindication for medications or techniques used in the study

Primary outcomes:
measure: effective analgesic interscalene block
timeFrame: in recovery unit (one hour after surgery)
Secondary outcomes:
Other outcomes:
Locations:
city: Abu Dhabi
country: United Arab Emirates
facility: Healthpoint Hospital
Study officials:
References:
Clinical trial NCT03646396: Effect of Sofosbuvir-daclatasuvir on Angiogenesis
Official title: Effect of Daclatasvir Plus Sofosbuvir on Angiogenesis in Egyptian Patients With Chronic HCV Infection
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: HCV Coinfection
Lead sponsor: Tanta University
Sponsor class: OTHER
First posted: 2018-08-24
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Intervention model description: Drug "sof-Dakla"
Primary purpose: TREATMENT

Brief summary: The study aimed at study of the Effect of Daclatasvir Plus Sofosbuvir on Angiogenesis in Egyptian Patients With Chronic HCV Infection

Detailed description: The study primary aim was at evaluation of the Effect of Daclatasvir Plus Sofosbuvir on Angiogenesis in Egyptian Patients With Chronic HCV Infection

Eligibility criteria: Inclusion Criteria:

* Chronic HCV patients

Exclusion Criteria:

* HCC.
* HIV or HBV.
* Malignancy.
* Pregnancy.

Primary outcomes:
measure: Number of patients with change in VEGF, TGFB1
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Tanta
country: Egypt
facility: Sherief Abd-Elsalam
Study officials:
affiliation: Clinical pharmacy Department- Tanta University
name: Eman h abd El-Razek, Msc
role: PRINCIPAL_INVESTIGATOR
affiliation: Clinical pharmacy Department- Tanta University
name: Tarek M Mostafa, Ph D
role: PRINCIPAL_INVESTIGATOR
affiliation: Hematology and Gastroenterology - Menoufia University
name: Nashwa Shebl, Ph D
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02511496: Status of Chronic Liver Disease in Hepatitis C Virus (HCV) Patients Coinfected With Human Immunodeficiency Virus (HIV) in Andalusia
Official title: Status of Chronic Liver Disease in Hepatitis C Virus (HCV) Patients Coinfected With Human Immunodeficiency Virus (HIV) in Andalusia
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Chronic Hepatitis C
Human Immunodeficiency Virus (HIV)
Lead sponsor: Maimónides Biomedical Research Institute of Córdoba
Sponsor class: OTHER
First posted: 2015-07-30
Enrollment: 2800
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The sample consists of all HIV-infected patients co-infected with an active chronic HCV.

Brief summary: This study evaluates the current situation and follow-up of chronic hepatitis C virus (HCV) infection in patients co-infected with human immunodeficiency virus (HIV) in Andalusia.

Detailed description: In subjects co-infected with HIV, treatment of chronic HCV infection is particularly complex and requires considerable resources, including a very high cost is likely to increase with new antivirals.

A precise knowledge of the situation in each hospital would facilitate adequate provision of personal and material resources needed to adequately address this disease in each center and in the Community as a whole. Because all or the vast majority of patients coinfected HIV / HCV are staffed by specialists who are part of Hepavir group and / or Sociedad Andaluza de Enfermedades Infecciosas (SAEI), they are ideal for carrying out this study.

Eligibility criteria: Inclusion Criteria:

* Patients over 18 with HIV infection and active chronic hepatitis or SVR after treatment.

Exclusion Criteria:

* None

Primary outcomes:
measure: Sustained virological response
timeFrame: Up to twelve months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)
name: Antonio Rivero Juárez
role: PRINCIPAL_INVESTIGATOR
References:
citation: Rivero-Juarez A, Guijo-Rubio D, Tellez F, Palacios R, Merino D, Macias J, Fernandez JC, Gutierrez PA, Rivero A, Hervas-Martinez C. Using machine learning methods to determine a typology of patients with HIV-HCV infection to be treated with antivirals. PLoS One. 2020 Jan 10;15(1):e0227188. doi: 10.1371/journal.pone.0227188. eCollection 2020.
Clinical trial NCT01181596: NICU-TECH RM9L-RS Probe ME Feasibility Study
Official title: NICU-TECH RM9L-RS Probe ME Feasibility Study
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Neonates
Keywords: neonates and infants, from the 23-week gestational (0.5 kg)
up to a 6 month old born at term (7 kg), for whom the PIV,
PAC, UAC, UVC or PICC catheter insertion is medically
indicated.
Lead sponsor: GE Healthcare
Sponsor class: INDUSTRY
First posted: 2010-08-13
Enrollment: 31
Sex: ALL
Minimum age (years): 23
Maximum age (years): 6
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: neonates and infants, from the 23-week gestational (0.5 kg) up to a 6 month old born at term (7 kg), for whom the PIV, PAC, UAC, UVC or PICC catheter insertion is medically indicated.

Brief summary: Use of a new ultrasound device designed for babies to look at the catheters in veins and arteries as well as the blood vessel itself. An observational study to assess the the clinicians perception of the ultrasound image quality as a tool to detect catheters in vessels.

Detailed description: The intent of the study is to confirm the maximum penetration of the NICU-Tech RM9L-RS probe. The investigators collected images on patients with PIV (Peripheral Intra Venous)/PAC (Peripheral Arterial Catheter) and central line catheters. The investigators collected images of deep vessel structures for offline processing to improve NICU-Tech algorithms for vessel segmentation.

Eligibility criteria: Inclusion Criteria:

* Neonates that are 23 gestational weeks at birth (and greater than 500 grams) to a 6 month old born infant at term (maximum weight 7 kg) who already have one or more lines placed (PIV/PAC/UVC/UACs/PICC) as part of their medical care. NO INFANT WILL HAVE A LINE PLACE FOR THE PURPOSE OF THIS STUDY

Exclusion Criteria:

* Neonates that are less than 23 gestational weeks at birth
* Neonates that are 23 gestational weeks at birth but are less than 500 grams in weight
* Patients weighing more than 7 kg.-Patients older than 6 months

Primary outcomes:
measure: Participants That Fulfilled All Study Procedures.
timeFrame: 1 day (day of procedure)
measure: Vessel Penetration of NICU-Tech RM9L-RS Probe
timeFrame: 1 day (day of procedure)
Secondary outcomes:
Other outcomes:
Locations:
city: San Diego
country: United States
facility: UCSD Medical Center
state: California
Study officials:
affiliation: UCSD Medical Center
name: Jae Kim, MD
role: PRINCIPAL_INVESTIGATOR
References: